Uromigos-ASCO

The UromigosThe Uromigos | June 7, 2022
Veda Giri discusses germline variants among African American males and specific genes related to prostate cancer.
Read More
The UromigosThe Uromigos | June 5, 2022
Data from the ENZAMET trial reconfirms survival benefit with enzalutamide in mHSPC, but the role of docetaxel is uncertain.
The UromigosThe Uromigos | June 5, 2022
Matt Galsky discusses research posters presented that cover the effects of HER2-targeting ADCs for urothelial cancer.
The UromigosThe Uromigos | June 4, 2022
Nazli Dizman covers an update on the CBM588 probiotic strain and its phase II trial.
The UromigosThe Uromigos | June 4, 2022
Amir Goldkorn, MD, discusses findings from a phase 2 bladder trial, responses to neoadjuvant chemotherapy, and more.
The UromigosThe Uromigos | June 3, 2022
Robert Jones, MD, talks about the hypothesis for ATLANTIS, its specific trial results, and more.
The UromigosThe Uromigos | June 3, 2022
Christopher W. Ryan, MD, shares long-awaited data about adjuvant everolimus in kidney cancer, the EVEREST trial, and results.
The UromigosThe Uromigos | June 18, 2021
Silke Gillessen gives a safety update from this EORTC study focusing on fractures.
The UromigosThe Uromigos | June 18, 2021
Chris Sweeney and Silke Gillessen give their opinion of recent data on radionuclides therapy in prostate cancer.
The UromigosThe Uromigos | June 10, 2021
Dr. Kosj Yamoah of Moffitt Cancer Center describes the work he presented at ASCO 2021.
The UromigosThe Uromigos | June 8, 2021
Dr. Nizar Tannir and the Uromigos discuss the phase 3 trial of cabozantinib +/- a glutaminase inhibitor in refractory mRCC.
The UromigosThe Uromigos | June 8, 2021
The Uromigos discuss an intriguing abstract that explores triplet therapy in metastatic hormone-sensitive prostate cancer.
The UromigosThe Uromigos | June 7, 2021
The Uromigos discuss a plenary presentation on adjuvant pembrolizumab versus placebo in high-risk resected RCC.
The UromigosThe Uromigos | June 7, 2021
Join the debate around pembrolizumab monotherapy in initial treatment of cisplatin-ineligible metastatic urothelial cancer.
The UromigosThe Uromigos | June 7, 2021
Matt Gowski takes a deeper dive into the phase 2 data of neoadjuvant chemo/nivolumab in muscle-invasive bladder cancer.
The UromigosThe Uromigos | June 7, 2021
The Uromigos and Andrea Necchi have a wide-ranging discussion of 3 interesting neoadjuvant IO-based phase 2 trials.
The UromigosThe Uromigos | June 7, 2021
Arjun Balar explains why, despite a negative trial, T cell stimulation plus checkpoint inhibition may warrant future study.
The UromigosThe Uromigos | June 6, 2021
Mike Morris explains how radionucleotides and PSMA-based therapeutics impact metastatic castration-resistant prostate cancer.
The UromigosThe Uromigos | June 6, 2021
The Uromigos and Monty Pal discuss data on microbiome modification's impact on immune-oncology clinical efficacy in mRCC.
The UromigosThe Uromigos | June 16, 2020
Dr. Peter Black talks about his BCG refractory NMIBC presentation at ASCO 2020 and its implications for the field.
Advertisement
Advertisement